Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias

Blood Cells, Molecules, and Diseases

Volumn 46, Issue 3, 2011, Pages 230-234

  Veiga, Camilla de S B ^a   Carneiro Lobo, Tatiana C ^a   Coelho, Cláudia J B P ^b   Carvalho, Silvia M F ^b   Maia, Raquel C ^c   Vasconcelos, Flávia C ^c   Abdelhay, Eliana ^c   Mencalha, André L ^c   Ferreira, Aline F ^d   Castro, Fabíola A ^d   Monteiro, Robson Q ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Protease activated receptor 1 (PAR 1); Thrombin

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, PAR-1; YOUNG ADULT;

EID: 79952102858     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.12.005     Document Type: Article

References (31)

1. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 2005, 3:1800-1814.
2. Vergnolle N., Wallace J.L., Bunnett N.W., Hollenberg M.D. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol. Sci. 2001, 22:146-152.
3. Whitehead I., Kirk H., Kay R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol. Cell. Biol. 1995, 15:704-710.
4. Even-Ram S.C., Uziely B., Cohen P., Grisaru-Granovsky S., Maoz M., Ginzburg Y., Reich R., Vlodavsky I., Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 1998, 4:909-914.
5. Tellez C., Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003, 22:3130-3137.
6. Depasquale I., Thompson W.D. Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. Histopathology 2008, 52:500-509.
7. Darmoul D., Gratio V., Devaud H., Lehy T., Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am. J. Pathol. 2003, 162:1503-1513.
8. Tantivejkul K., Loberg R.D., Mawocha S.C., Day L.L., John L.S., Pienta B.A., Rubin M.A., Pienta K.J. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J. Cell. Biochem. 2005, 96:641-652.
9. Grisaru-Granovsky S., Salah Z., MAOZ M., Pruss D., Beller U., Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int. J. Cancer 2005, 113:372-378.
10. Ribeiro F.S., Simão T.A., Amoedo N.D., Andrello N.A., Lopes L.R., Acatauassu R., Rumjanek F.D., Albano R.M., Pinto L.F.R., Monteiro R.Q. Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncol. Rep. 2009, 21:1599-1604.
11. Yin Y.J., Salah Z., Maoz M., Even-Ram S.C., Ochayon S., Neufeld G., Katzav S., Bar-Shavit R. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J. 2003, 17:163-174.
12. Shi X., Gangadharan B., Brass L.F., Ruf W., Mueller B.M. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol. Cancer Res. 2004, 2:395-402.
13. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
14. Salah Z., Maoz M., Pokroy E., Lotem M., Bar-Shavit R., Uziely B. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol. Cancer Res. 2007, 5:229-240.
15. Mari B., Imbert V., Belhacene N., Far D.F., Peyron J.F., Pouysségur J., Obberghen-Schilling E.V., Rossi B., Auberger P. Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. J. Biol. Chem. 1994, 269:8517-8523.
16. Bar-Shavit R., Hruska K.A., Kahn A.J., Wilner G.D. Thrombin chemotactic stimulation of HL-60 cells: studies on thrombin responsiveness as a function of differentiation. J. Cell. Physiol. 1987, 131:255-261.
17. Schiller H., Bartscht T., Arlt A., Zahn M.O., Bruhn T., Bruhn H.D., Gieseler F. Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro. Int. J. Clin. Pharmacol. Ther. 2002, 40:329-335.
18. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985, 103:620-625.
19. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 352:804-815.
20. Copelan E.A., McGuire E.A. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995, 85:1151-1168.
21. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
22. Shpacovitch V., Feld M., Hollenberg M.D., Luger T.A., Steinhoff M. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J. Leukoc. Biol. 2008, 83:1309-1322.
23. Estey E., Döhner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
24. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
25. Stein E., McMahon B., Kwaan H., Altman J.K., Frankfurt O., Tallman M.S. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract. Res. Clin. Haematol. 2009, 22:153-163.
26. Hair G.A., Padula S., Zeff R., Schmeizl M., Contrino J., Kreutzer D.L., de Moerloose P., Boyd A.W., Stanley I., Burgess A.W., Rickles F.R. Tissue factor expression in human leukemic cells. Leuk. Res. 1996, 20:1-11.
27. Nadir Y., Katz T., Sarig G., Hoffman R., Oliven A., Rowe J.M., Brenner B. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica 2005, 90:1549-1556.
28. López-Pedrera C., Dobado-Berrios P.M., Ros R., Torres A., Garcia-Navarro S., Jardi M., Felez J., Velasco F. Signal transduction pathways underlying the expression of tissue factor and thrombomodulin in promyelocytic cells induced to differentiate by retinoid acid and dibutyryl cAMP. Thromb. Haemost. 2001, 85:1031-1036.
29. Tallman M.S., Lefèbvre P., Baine R.M., Shoji M., Cohen I., Green D., Kwaan H.C., Paietta E., Rickles F.R. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J. Thromb. Haemost. 2004, 2:1341-1350.
30. Barbarroja N., Arístides-Torres L., Hernandez V., Martín C., Dorado G., Torres A., Velasco F., Lopez-Pedrera C. Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leuk. Lymphoma 2007, 48:1187-1199.
31. Carneiro-Lobo T.C., Konig S., Machado D.E., Nasciutti L.E., Forni M.F., Francischetti I.M., Sogayar M.C., Monteiro R.Q. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J. Thromb. Haemost. 2009, 7:1855-1864.